


**DOCUMENT MADE AVAILABLE UNDER THE
PATENT COOPERATION TREATY (PCT)**

International application number:	PCT/EP2017/068759
International filing date:	25 July 2017 (25.07.2017)
Document type:	Certified copy of priority document
Document details:	Country/Office: US
	Number: 62/474,383
	Filing date: 21 March 2017 (21.03.2017)
Date of receipt at the International Bureau:	28 September 2017 (28.09.2017)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a),(b) or (b-bis)

7643489



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

July 21, 2017

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 62/474,383
FILING DATE: *March 21, 2017*

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS *US62/474,383*



Certified by

Michelle K. Lee

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	00007-0037-00600
		Application Number	
Title of Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.			

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Eamon		BRADY		
Residence Information (Select One) ☐ US Residency ☒ Non US Residency ☐ Active US Military Service					
City	County Galway	Country of Residence ⁱ		IE	
Mailing Address of Inventor:					
Address 1		Doon, Kilrickle, Loughrea			
Address 2					
City	County Galway	State/Province			
Postal Code			Country ⁱ	IE	
Inventor 2					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	David		VALE		
Residence Information (Select One) ☐ US Residency ☒ Non US Residency ☐ Active US Military Service					
City	County Galway	Country of Residence ⁱ		IE	
Mailing Address of Inventor:					
Address 1		Froghollow, Lacklea Road, Barna			
Address 2					
City	County Galway	State/Province			
Postal Code			Country ⁱ	IE	
Inventor 3					Remove
Legal Name					

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	00007-0037-00600
		Application Number	
Title of Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		

Prefix	Given Name	Middle Name	Family Name	Suffix
	Michael		GILVARRY	
Residence Information (Select One) ☐ US Residency ☒ Non US Residency ☐ Active US Military Service				
City	County Galway	Country of Residence ⁱ	IE	

Mailing Address of Inventor:

Address 1	Ballinakillew, Headford			
Address 2				
City	County Galway	State/Province		
Postal Code		Country ⁱ	IE	
Inventor 4				Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Brendan		CASEY	
Residence Information (Select One) ☐ US Residency ☒ Non US Residency ☐ Active US Military Service				
City	Galway	Country of Residence ⁱ	IE	

Mailing Address of Inventor:

Address 1	87 Ros Ard, Cappagh Road, Barna			
Address 2				
City	Galway	State/Province		
Postal Code		Country ⁱ	IE	
Inventor 5				Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Marto		HOARY	
Residence Information (Select One) ☐ US Residency ☒ Non US Residency ☐ Active US Military Service				
City	Galway	Country of Residence ⁱ	IE	

Mailing Address of Inventor:

Address 1	24 Cashelmara, Salthill			
Address 2				
City	Galway	State/Province		
Postal Code		Country ⁱ	IE	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	00007-0037-00600
		Application Number	
Title of Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		

Inventor 6 Remove				
Legal Name				
Prefix	Given Name	Middle Name	Family Name	Suffix
	Adnan		SIDDIQUI	
Residence Information (Select One) ☐ US Residency ☒ Non US Residency ☐ Active US Military Service				
City	Galway	Country of Residence ⁱ	IE	
Mailing Address of Inventor:				
Address 1	c/o Neuravi Limited			
Address 2	Block 3, Ballybrit Business Park			
City	Galway	State/Province		
Postal Code	H91 K5YD	Country ⁱ	IE	
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button. Add				

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).			
☐ An Address is being provided for the correspondence information of this application.			
Customer Number	108449		
Email Address	docketing@bomcip.com	Add Email	Remove Email

Application Information:

Title of the Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		
Attorney Docket Number	00007-0037-00600	Small Entity Status Claimed	☒
Application Type	Provisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)	18	Suggested Figure for Publication (if any)	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	00007-0037-00600
		Application Number	
Title of Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	☒ Customer Number	☐ US Patent Practitioner	☐ Limited Recognition (37 CFR 11.9)
Customer Number	108449		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.

When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status			Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	00007-0037-00600
		Application Number	
Title of Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)ⁱ the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Application Number	Country ⁱ	Filing Date (YYYY-MM-DD)	Access Code ⁱ (if applicable)

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button.

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.

☐ NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	00007-0037-00600
		Application Number	
Title of Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	00007-0037-00600
		Application Number	
Title of Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.			
Applicant 1			
If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.			
Clear			
☒ Assignee		☐ Legal Representative under 35 U.S.C. 117	
☐ Person to whom the inventor is obligated to assign.		☐ Person who shows sufficient proprietary interest	
If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:			
Name of the Deceased or Legally Incapacitated Inventor:			
If the Applicant is an Organization check here. ☒			
Organization Name	Neuravi Limited		
Mailing Address Information For Applicant:			
Address 1	Block 3		
Address 2	Ballybrit Business Park		
City	Galway	State/Province	
Country	IE	Postal Code	H91 K5YD
Phone Number		Fax Number	
Email Address			
Additional Applicant Data may be generated within this form by selecting the Add button.			

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	00007-0037-00600
		Application Number	
Title of Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		

Assignee 1			
Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.			
If the Assignee or Non-Applicant Assignee is an Organization check here. ☒			
Organization Name	Neuravi Limited		
Mailing Address Information For Assignee including Non-Applicant Assignee:			
Address 1		Block 3	
Address 2		Ballybrit Business Park	
City	Galway	State/Province	
Country ⁱ	IE	Postal Code	H91 K5YD
Phone Number		Fax Number	
Email Address			
Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button.			

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Jessica F. Winchester/		Date (YYYY-MM-DD)	2017-03-21	
First Name	Jessica F.	Last Name	Winchester	Registration Number	65285
Additional Signature may be generated within this form by selecting the Add button.					

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	00007-0037-00600
		Application Number	
Title of Invention	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL		

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc Code: **TR.PROV**

Document Description: Provisional Cover Sheet (SB16)

PTO/SB/16 (11-08)

Approved for use through 05/31/2015. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Provisional Application for Patent Cover Sheet This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c)					
Inventor(s)					
Inventor 1					Remove
Given Name	Middle Name	Family Name	City	State	Country ;
Eamon		BRADY	County Galway		IE
Inventor 2					Remove
Given Name	Middle Name	Family Name	City	State	Country ;
David		VALE	County Galway		IE
Inventor 3					Remove
Given Name	Middle Name	Family Name	City	State	Country ;
Michael		GILVARRY	County Galway		IE
Inventor 4					Remove
Given Name	Middle Name	Family Name	City	State	Country ;
Brendan		CASEY	Galway		IE
Inventor 5					Remove
Given Name	Middle Name	Family Name	City	State	Country ;
Marto		HOARY	Galway		IE
Inventor 6					Remove
Given Name	Middle Name	Family Name	City	State	Country ;
Adnan		SIDDIQUI	Galway		IE
All Inventors Must Be Listed – Additional Inventor Information blocks may be generated within this form by selecting the Add button.					Add
Title of Invention		CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL			
Attorney Docket Number (if applicable)		00007-0037-00600			
Correspondence Address					

Doc Code: **TR.PROV**

Document Description: Provisional Cover Sheet (SB16)

PTO/SB/16 (11-08)

Approved for use through 05/31/2015. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Direct all correspondence to (select one):	
☒ The address corresponding to Customer Number	☐ Firm or Individual Name
Customer Number	108449

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.	
☒ No.	
☐ Yes, the invention was made by an agency of the United States Government. The U.S. Government agency name is:	
☐ Yes, the invention was under a contract with an agency of the United States Government. The name of the U.S. Government agency and Government contract number are:	

Doc Code: **TR.PROV**

Document Description: Provisional Cover Sheet (SB16)

PTO/SB/16 (11-08)

Approved for use through 05/31/2015. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Entity Status

Applicant asserts small entity status under 37 CFR 1.27 or applicant certifies micro entity status under 37 CFR 1.29

- ☒ Applicant asserts small entity status under 37 CFR 1.27
- ☐ Applicant certifies micro entity status under 37 CFR 1.29. Applicant must attach form PTO/SB/15A or B or equivalent.
- ☐ No

Warning

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

Signature

Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/Jessica F. Winchester/			Date (YYYY-MM-DD)	2017-03-21
First Name	Jessica F.	Last Name	Winchester	Registration Number (If appropriate)	65285

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **This form can only be used when in conjunction with EFS-Web. If this form is mailed to the USPTO, it may cause delays in handling the provisional application.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that : (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

“A clot retrieval system for removing occlusive clot from a blood vessel”

5 Field of the Invention

This invention relates to devices intended for removing acute blockages from blood vessels. Acute obstructions may include clot, misplaced devices, migrated devices, large emboli and the like. Thromboembolism occurs when part or all of a thrombus breaks away from the blood vessel wall. This clot (now called an embolus) is then carried in the direction of blood flow.

- 10 An ischemic stroke may result if the clot lodges in the cerebral vasculature. A pulmonary embolism may result if the clot originates in the venous system or in the right side of the heart and lodges in a pulmonary artery or branch thereof. Clots may also develop and block vessels locally without being released in the form of an embolus - this mechanism is common in the formation of coronary blockages. The invention is particularly suited to removing clot from
- 15 cerebral arteries in patients suffering acute ischemic stroke (AIS), from coronary native or graft vessels in patients suffering from myocardial infarction (MI), and from pulmonary arteries in patients suffering from pulmonary embolism (PE) and from other peripheral arterial and venous vessels in which clot is causing an occlusion.

20 Background

Despite a wealth of information in the literature on the clotting cascade and on the biochemistry and etiology of thrombus in humans, remarkably little information is available on the physical and mechanical properties of this material. These properties are very pertinent to the interaction between thrombus and clot retrieval catheters and devices and the surrounding vasculature

25 during mechanical thrombectomy of vessels occluded by thrombus material. Through extensive experimentation and research into thrombus material the inventors have discovered aspects of the properties and behaviour of certain clot/thrombus types that help to explain why these clot types can be particularly challenging to retrieve. Some of these findings are described in our WO2012/120490A, the entire contents of which are herein incorporated by reference.

30

Clot is essentially a living polymer, comprising a matrix of intertwined and cross linked fibrin strands within which are situated red and white blood cells, platelets and numerous other proteins and components. The inventors have discovered that the mechanical properties of a clot are strongly influenced by the relative percentages of fibrin and red blood cells, and that clots with a

high (and highly organised) fibrin content and low red blood cell content tend to be much firmer and more cohesive than clots of a higher red cell content. Such clots have also been found to have a higher coefficient of friction, or in other words to be “stickier”. These firm and sticky clots can be very challenging to remove from a vessel.

5

Clots with a low fibrin content and high red cell content have been found to be less cohesive and more friable and to have a lower coefficient of friction than the more organised fibrin rich clots previously described. These properties mean that such clots may be easier to dislodge from the site of occlusion, but may tend to fragment during the retrieval process, with the consequent risk of loss of clot fragments into distal or new vascular territories.

10

Furthermore the inventors have discovered that the fibrin matrix of the clot can result in the clot material exhibiting viscoelastic behaviour in certain circumstances. A series of experiments were carried out in which a range of clots of varying fibrin content were tested. The clot samples were held in a receptacle and an indenter was placed on the surface of the clot and subject to a fixed indenting force. The depth of penetration of the indenter into the clot was measured as a function of time for each clot type. Clots with a high fibrin content and low red blood cell content were found to exhibit the greatest viscoelastic effect, with the indenter effectively “creeping” into the clot over a period of several minutes, whereas with low fibrin content clots the indenter tended to almost fully penetrate the clots in a matter of seconds. greater levels of organisation (and clot maturity) of the fibrin structure resulted in firmer clots which were penetrated to a much lesser extent by the indenter.

15

20

This behaviour combined with the higher frictional properties of fibrin rich clots tend to make these clot types particularly challenging to retrieve by mechanical thrombectomy. Conventional stent-retrievers may find it difficult to penetrate and grip these firm clots, and the high level of friction they maintain with the vessel wall can result in a tendency for the clot to roll and compress.

25

Attempts to aspirate such clots into a catheter can also be very challenging as the clot must be deformed in order to fit into the catheter lumen, and the energy required to deform such clots is not easily attained by aspiration. The high frictional coefficient of these clot types adds further to the challenge of aspirating them into the distal mouth of a catheter. Even maintaining a suction grip on such clots so that they can be retracted to the safety of a more proximal guide or

30

sheath is very difficult, as these firm clots do not tend to deform and reshape easily and thus do not readily conform to the shape of the catheter tip in order to effect a seal and consequent suction grip.

5 Statements of the Invention

This invention solves the challenge of aspirating fibrin rich clot material into a catheter by addressing the key challenges of 1) the friction between the clot and the catheter and 2) the energy/work required to deform these firm clots as they are aspirated into the catheter tip.

10 Conventional clot aspiration involves inserting a catheter (sometimes referred to as an intermediate catheter or aspiration catheter or distal access catheter) into the patient's vasculature and advancing the catheter up to the occlusive clot. A syringe or vacuum pump is then attached to the proximal end of the catheter and a vacuum applied to attempt to suck the clot into the catheter tip and out through the catheter. The level of the vacuum applied can be controlled to a
15 very limited extent by the force applied to the syringe or by the pump setting, and typically a fairly constant pressure drop of 500mmHg to 760mmHg (or "full" vacuum) is applied. The difference in pressure between the blood vessel in which the clot is situated and the interior of the catheter creates a pressure gradient (which may exceed 760mmHg as the patient's blood pressure is higher than atmospheric pressure) which urges the clot into the catheter mouth.

20

The diameter of the clot however is greater than the diameter of the catheter therefore for a clot to be aspirated into a catheter the clot must deform and elongate to fit into the catheter tip. The energy to deform the clot to fit into the catheter is effectively an extrusion energy as the catheter tip acts as a form of extrusion die for the clot. This extrusion energy is related to the fibrin
25 content of the clot with higher fibrin clots requiring increased extrusion energy to aspirate the clot into the catheter. Current techniques to aspirate the clot involve applying a steady state vacuum to the tip of the catheter; however in many cases this does not provide sufficient energy to aspirate the clot fully into the catheter. Subsequent retrieval of the catheter either does not dislodge the clot or dislodges the partially retrieved clot and creates the risk of losing the
30 partially exposed clot into a side branch or new vessel creating an ENT (Embolization in New Territory).

This invention improves the ability of a catheter to aspirate a clot fully, including clots which have higher fibrin content. As stated above, vacuum is applied to the catheter tip to create a

pressure differential between the catheter and the blood vessel with the aim of aspirating or sucking the clot into the catheter and out of the vasculature. When the apparatus detailed in this invention is operating, the steady state vacuum normally applied at the tip of the catheter is modified to a pulsatile or wave configuration so that in one design configuration, the pressure differential between the catheter tip and the blood vessel plotted against time resembles a sine wave. The application of the aspiration force to the clot in a wave or pulsatile configuration applies an 'impact load' to the clot which can deform the clot and overcome the resistance or extrusion energy required to get the clot into the catheter more quickly and effectively than applying a continuous or steady aspiration force.

10

In addition, when clot occludes the distal tip of an aspiration catheter, part of the clot is inside the tip of the catheter. Testing has shown that compression and manipulation of thrombus increases the friction of the clot. Therefore compression of the clot at the tip of the catheter further increases the static friction between the clot and the inside surface of the catheter tip. The static friction between the clot and the catheter needs to be overcome to allow the clot to be aspirated fully into the catheter. The application of a pulsatile force to the clot can cause the clot to vibrate or move slightly proximally and distally, so that the interaction between the clot and the internal surface of the catheter changes from static friction to a dynamic friction interaction. Dynamic friction of clot has been shown in our testing to be lower than static friction therefore the total force to remove the clot is reduced when using the apparatus detailed in this invention.

15
20

The fibrin matrix of a thrombus is porous and red blood cells can migrate and flow within the matrix depending on pressure differentials and fibrin density. Applying a pulsatile energy or vacuum at the catheter tip can promote this movement of clot elements, allowing the red blood cells to be aspirated out of the fibrin matrix. The thrombus is then easier to aspirate as the red blood cell content of the clot decreases facilitating deformation of the fibrin matrix with reduced energy.

25

This invention is suitable for the aspiration of clots with varying fibrin content from 0% to 100%, and is particularly suited to the aspiration of clot or thrombus which has fibrin content greater than 30%. The invention relates to the removal of a blood clot from the human vascular system. In particular it more specifically relates to the removal of a blood clot from the neurovasculature including the anterior and posterior circulation. Techniques and means of removing blood clots, or clotted blood particles in the form of emboli are already well known

30

and established in use. When the presence of a clot is identified in the body it may be treated by best medical treatment (BMT) in the form of medication or by surgical intervention. Surgical intervention can involve the use of mechanical means to dislodge and remove the clot. Blood clots may also be identified and referred to as emboli. Surgical intervention may be in the form of minimally invasive endovascular intervention where by the clot or embolism is accessed within the blood vessel by the distal end of a catheter that has been introduced within the arterial system at a remote location such as the Common Iliac artery. This is well known and relevant to the background of this invention.

- 10 Referring to an endovascular intervention described herein one of the means used to effect the removal of a clot through surgical endovascular intervention, is to use what is commonly referred to as 'aspiration' of the clot mass through a catheter. Aspiration is a technique whereby negative pressure or suction can be applied to the clot mass within the blood vessel through the distal end of a catheter, the catheter being connected at the proximal end to a vacuum source.

15

It is well known that there are clots which cannot be moved or removed even with the maximum intensity of vacuum or aspiration being applied to them. The present invention relates to but is not limited to this situation and to the removal of these types of arduous blood clots. This invention presents and describes a method of removing blood clots by applying a pulsatile energy comprising of a sequence of alternating forces through the distal tip of a catheter which is adjacent to or abutting the blood clot wherein this sequence of pulsatile forces applied to the clot and having the effect of deforming the clot in addition to aspirating the clot back through the catheter. The pulsatile force may also be described as being in the form of a sequence of pulses applied to the clot over a period of time, commonly referred to as frequency. Each pulse comprises of a sequential positive and negative volumetric displacement of fluid at the catheter distal tip. This cyclical positive and forward projecting pressure followed by negative pressure can be described mathematically in general but not limited to a sinusoidal function.

- It is known that the aspiration function applies a negative force in the form of negative pressure of approximately 500 – 760 millimetres of mercury (mm Hg) at the tip of the catheter creating a flow from the distal to the proximal end of the catheter and recovering the content of this flow in a container which is part of the circuit and located close to the vacuum source. This pulsatile sequence of positive and negative pressures are applied through the catheter in conjunction with

the aspirated negative pressure. The source of the pulsatile force is separate and independent of the source of the aspirated suction.

Waveforms which represent the sequence of pulsatile positive and negative pressures constitute inventive steps.

5

It is well known that there are clots which cannot be moved or removed by the level of aspiration being applied to them. The present invention relates to the removal of these types of clots. The invention describes in method of applying pulsatile force through a catheter at the distal tip to the clot which has the effect of aspirating the clot in one or more pieces and retrieving it into the
10 catheter. The pulsatile force is in the form of a sequence of pulses applied to the clot over a period of time. Each pulse comprises of a sequential positive and negative volumetric displacement of fluid at the catheter distal tip or varying negative volumetric displacements.

This period cycle of varying negative pressure can be described mathematically in general but
15 not limited to a sinusoidal function. The pulsatile sequence of pressures are applied in conjunction with the application of a steady state negative pressure / suction force. It has also been observed as a further inventive step that the blood clot can be recovered by applying the pulse without any aspiration.

20 With regard to the sinusoidal profile of the pressure emitted at the tip of the catheter then the pressure profile may vary about a pure sine wave in the following ways. A sine wave can be described for this purpose as having four components to it which are equal in frequency and amplitude but may be positive or negative. If the first part of the wave is an increasing pressure induced by the forward motion of a piston then the second part will be a negative pressure
25 caused by a reverse motion of the piston. The piston is driven by a shaft or connecting rod that is rotated in a cycle along the length of the shaft and thus directing the piston in a forward and reverse motion. In terms of the sine wave describing this motion the first part of the curve indicating the increasing pressure is referred to as the rise time. The next part of the curve which represents a reverse motion of the piston and results in negative pressure at the catheter tip, this
30 is referred to as the fall time or the decay time. The curve has one positive peak and one negative peak in each cycle. In a sequence of cycles constituting a sequence of pulses, the time from peak to peak is the same in a sine wave. The peak of a sine wave can be said to have no duration as the intensity or amplitude of the wave is changing continuously even as it transitions from positive to negative.

The present invention describes wave profiles applied at the catheter tip which can be at variance to a pure sine wave in the following manner. One is that the rise time may not be equal to the decay time. The rise time may be longer or shorter duration than the fall time duration. Secondly
5 the peak of the wave may have a duration or a dwell time. The purpose of the dwell time is to allow fluid or blood some time to fill into the space in the piston chamber or time to pass through the orifice at the end of the chamber.

The nature of the pulse applied to dislodge and retrieve the blood clot can be defined by the
10 following variables or control aspects:

- Reciprocation
- Frequency
- Amplitude
- Rise time
- 15 Dwell time
- Decay / Fall time

While the application of the reciprocal motion of both positive and negative displacement in sequence is not well known, there are a number of methods available that are well known for
20 reciprocal motion as described.

One is a purely mechanical cyclical drive system whereby the moving piston within the chamber is connected to crank shaft or the outer radius of a disk which is rotated so as to drive the piston to and fro. This to and fro distance is known as the stroke length. It is well known to use this
25 method in positive displacement pumps but not positive and negative displacement in sequence.

Another well known method of generating reciprocal motion is by electromechanical means using electromagnetic induction whereby a magnetic field is induced in a coil of wire or alternately in two coils of wire for more control over different forces in each direction to create
30 the forces necessary to move the piston to and fro in the chamber

The source of the power can be an alternating current and voltage or a direct current whereby the positive and negative cycles are achieved by switching mode control circuit.

As mentioned heretofore the cyclical motion which results in a symmetrical sinusoidal wave form of positive and negative pressure is the simplest. It may be desirable to alter the shape of the wave form so that the negative pressure is greater than the positive pressure or so that the rate of increase in pressure is greater of less than the rate of decline in pressure. It is recognised
5 herein that there may be an advantage in having no or less positive pressure than negative pressure so that vibration of the clot mass is reduced. It is recognised and presented as an inventive step that the introduction of dwell time on the peak and the trough of the wave form allows time for the fluid displacement to take place on both the positive and negative parts of each cycle. This is more relevant and important as the frequency of the cycles increases.

10

According to the invention there is provided a system for removing occlusive clot from a blood vessel comprising a vacuum source and collection chamber, a catheter to communicate the negative pressure to the location of the clot, and an apparatus to modify a steady state vacuum provided by a vacuum source to a series of pulses or a waveform configuration. In one iteration
15 this apparatus contains a mechanical drive system whereby a moving piston within a fluid chamber is connected to crank shaft or the outer radius of a disk which is rotated so as to drive the piston to and fro creating a positive and negative fluid displacement in sequence. This variable fluid displacement is combined with the steady state vacuum or negative displacement provided by the vacuum pump to produce a waveform pressure differential between the catheter
20 and the blood pressure at the tip of the catheter adjacent to the clot in the vasculature.

In one iteration the reciprocal motion to create the positive and negative fluid displacement is generated by electromechanical means using electromagnetic induction whereby a magnetic field is induced in a coil of wire or alternately in two coils of wire for more control over different
25 forces in each direction to create the forces necessary to move a piston to and fro in the fluid chamber.

In another iteration the fluid displacement is generated by moving the piston using other electromechanical means such as the piezoelectric effect.

30

In another iteration the fluid displacement is generated using other mechanical means such as a pneumatic drive.

In one configuration of the invention, the apparatus to create the pulsatile or waveform pressure differential is separate to the vacuum pump and chamber and is connected through tubing and connectors. In another iteration the apparatus of the invention and the vacuum pump are integrated in a single unit.

5

In one embodiment of the invention the piston to generate the pressure differential at the catheter tip is located within the catheter body which acts as the fluid chamber. The piston is moved proximally and distally in the catheter through a linear connection to a drive system located at the proximal end of the catheter. Alternatively the piston is moved in the catheter through
10 electronic means positioned within the catheter.

In one configuration of the invention, the apparatus to create the fluid displacement to produce a waveform pressure differential contains a single piston in a fluid chamber which is moved forward and back using a mechanical or electromechanical drive. In a different configuration of
15 the apparatus multiple fluid chambers with pistons are connected to facilitate complex waveforms. The displacement output of the apparatus can then be a summation of the displacements of each piston which can be programmed to operate independently.

In one iteration of the device the piston used to create the fluid displacement is similar to a
20 syringe with a moving seal between the piston and the fluid chamber. In another iteration other known hydraulic cylinder configurations are used to produce different waveform configurations.

In another iteration of the invention the tip of the catheter is vibrated by electromechanical means to reduce the friction between the catheter and the clot and help overcome the extrusion or
25 deformation energy required to aspirate the clot. The catheter tip vibration can be combined with a large aspiration lumen with a cross sectional area greater or equivalent to a 0.030" diameter lumen and in the preferred embodiment has a cross sectional area greater or equivalent to a 0.040" diameter lumen. The catheter with the vibrating tip may be used with a steady state aspiration vacuum or with the waveform pressure differential as described elsewhere in the
30 patent. The frequency of the tip vibration may range from 5 Hz to ultrasonic frequencies of greater than 20,000 Hz.

Also according to the invention there is provided a method of removing occlusive clot from a blood vessel comprising the steps of:-

providing a guide catheter or sheath and an intermediate catheter, the intermediate catheter having a distal mouth and being configured such that it is advancable within the lumen of the
5 guide catheter;

inserting the guide catheter into a first vessel proximal of an occlusion;

connecting the proximal end of the intermediate catheter to an aspiration source which consists of a vacuum pump, a collection chamber and the apparatus of the invention;

advancing the intermediate catheter through the lumen of the guide catheter until the tip of the
10 intermediate catheter extends distal of the guide catheter into a vessel adjacent to the occlusion;
applying steady state aspiration to the proximal end of the intermediate catheter;
the intermediate catheter being configured to direct said aspiration through the distal lumen of the intermediate catheter to aspirate the clot into the mouth of said intermediate catheter.

15 If the clot is not aspirated switch on the apparatus of the invention to provide a waveform pressure differential between the catheter and the blood pressure surrounding the clot. The waveform pressure differential overcomes the extrusion energy of the clot and reduces friction between the clot and the catheter so that the clot can be aspirated through the intermediate catheter into the collection chamber and out of the vasculature.

20

In one embodiment of the invention, this waveform resembles a sine wave with a fixed frequency and amplitude, and equal rise and decay times.

In another embodiment of the invention, the frequency or time between peaks of the waveform
25 may vary and increase or decrease with time. A repeating frequency pattern may also be utilised such as multiple high frequency pulses followed by a number of low frequency pulses.

Similarly in another embodiment the amplitude of the waveform may vary with time and consist of increasing or decreasing amplitudes or a combination of different amplitude pulses.

30

In another embodiment the rise and decay times of the waveform may vary such that the decay time is shorter than the rise time or vice versa, or a combination of different rise and decay times may be beneficial in aspirating the clot, for example, a saw tooth waveform.

Another wave pattern utilised in an embodiment of the invention is a truncated or square wave pattern where a dwell time is incorporated into the wave cycle at the peak or trough of the wave or at both times. A dwell time may also be incorporated into a wave pattern at any point in the cycle, for example, producing a step wave pattern.

5

In another embodiment of the device the amplitude of the pressure differential is such that positive pressure may be applied to the clot for a fraction of the time of the wave cycle to increase the impact load applied to the clot.

- 10 In one embodiment of the invention the waveform is a combination of a number of the waveforms or features described elsewhere in this patent. In another embodiment, the invention may be programmable to apply specific pressure differential waveforms to the catheter tip which may be optimised for different clot types, for example, a pre-programmed optimized waveform may be applied for a fibrin rich clot which would be different to the waveform optimized for an
15 erythrocyte rich clot.

Also provided are additional variants of this method, including:

A method as described above in which the waveform pressure differential is applied to the intermediate catheter as it approaches the occlusion for the first time.

20

An additional variant of this method is to apply the waveform pressure differential to the guide catheter or sheath if an intermediate catheter is not being used in the procedure. Alternatively the waveform pressure differential can be applied to both the intermediate catheter and the guide catheter at the same time.

25

- The waveform or pulsatile pressure differential applied to the intermediate catheter described in this patent can also be used when the intermediate catheter is used in conjunction with a stentriever device. The waveform pressure differential reduces the friction between the clot and the catheter and helps to deform the clot. This gives additional benefits of reducing the shear
30 forces acting on the clot as it is retrieved into the intermediate catheter by the stentriever device.

According to the invention there is provided a system for removing occlusive clot from a blood vessel comprising:-

a catheter; and

an apparatus for generating a pulsatile vacuum force to pulse the pressure gradient at a distal end of the catheter.

In one case the apparatus comprise a vacuum pump and a pulse generator.

5

In one embodiment the pulse generator is integral with the vacuum pump.

In another embodiment the pulse generator is separate from the vacuum pump.

10 The pulse generator in one case may be located between the vacuum pump and the proximal end of the catheter.

There may be a flexible tubing between the vacuum pump and the proximal end of the catheter.

15 In one embodiment the pulse generator is applied to the flexible tubing.

The pulse generator in one case comprises a reciprocating plunger.

The pulse generator in another case comprises a rotatable cam.

20

The cam may comprise an outer bearing to minimise drag on the tubing. The outer bearing may comprise a sliding outer layer.

In one case the flexible tubing is uniform cross section along the length thereof.

25

In one embodiment the flexible tubing is of variable cross section along the length thereof.

The system may comprise a controller for controlling the apparatus for generating a pulsatile vacuum source. The controller may be adapted or configured to vary the pressure over time in a

30 waveform.

In one case the waveform has a fixed frequency and amplitude, and equal rise and decay times.

In another case the waveform has a varying frequency with time.

35

The waveform may have varying amplitude with time.

The waveform may have a different rise and decay time.

In one case the waveform rise and decay times change with time.

In some cases the waveform is a truncated or square waveform incorporating a dwell time at the
5 peak and trough of each wave.

The waveform may incorporate one or more dwell times within each wave producing a stepped wave configuration.

10 The invention also provides a method for removing occlusive clot from a blood vessel comprising the steps of:-

delivering a catheter to a location adjacent to an occlusive clot; and
applying a pulsatile vacuum to the clot using the catheter.

15 The method in some cases comprises the step of varying the pressure over time in a waveform.

The waveform may have a fixed frequency and amplitude, and equal rise and decay times.

The waveform may have a varying frequency with time.

20

The waveform may have varying amplitude with time.

The waveform may have a different rise and decay time.

25 The waveform rise and decay times may change with time.

The waveform may be a truncated or square waveform incorporating a dwell time at the peak and trough of each wave.

30 The waveform may incorporate one or more dwell times within each wave producing a stepped wave configuration.

In one embodiment the system comprises a canister which is configured to receive aspirated blood or material.

35

In one case the system comprises a vacuum pump which is connected to the canister. The vacuum may be drawn through the canister.

5 In one embodiment the system comprises a first vacuum pulse generator. In one case the system comprises a second vacuum pulse generator. The vacuum pulse generators may be configured to operate separately, at the same time, or at different times to vary the vacuum pulse generated.

In one case the first pulse generator comprises a valve having a housing and an element which is rotatable and/or oscillatable in the housing.

10

In one case the second pulse generator is adapted to engage a flexible tube. The second vacuum pulse generator may comprise a rotatable cam.

15 In another case the first vacuum pulse generator comprises a pump. The system may further comprise non-return valves located on both sides of the pump.

In a further case the system comprises a canister configured to receive aspirated blood or material and the first pulse generator comprises an obturator which is movable through the canister.

20

Brief Description of the Drawings

The invention will be more clearly understood from the following description of some embodiments thereof, given by way of example only, with reference to the accompanying
25 drawings, in which:

Fig. 1 is a view of a clot lodged in a representation of a similar cerebral vascular tubular network to the network in the brain for the purposes of describing the invention;

30 Fig. 2 illustrates by way of example only that the source of the aspiration or continuous negative suction and the source of the pulsatile pressure gradient are both combined to common effect through the catheter;

35 Fig. 3 shows the complete circuit interfacing with the circulation system in schematic form only;

Figs. 4A to 4C show by way of example only a means of generation cyclical motion which will generate the pressure differential waveform at the catheter distal tip;

5 Figs. 5A to 5E illustrate a number of possible wave form profiles representing positive and negative pressure pulses that are possible to generate with the reciprocation drive;

Fig. 6 is one example of a motorised reciprocal drive with variable speed;

10 Fig. 7 shows the distal tip of a catheter touching or abutting a blood clot that is lodged in a circuit representing cerebral vascular complexity;

Fig. 8 shows the distal tip of a catheter firmly engaged in a blood clot that is lodged in a circuit representing cerebral vascular complexity - this is as a result of aspiration or suction at a rate of -500 mm Hg;

15 Fig. 9 shows that the clot in Fig. 8 has been aspirated into the catheter following a small number of reciprocation pulses (3 to 5);

20 Figs. 10A – D are schematic illustrations of a clot being aspirated into a catheter inside a blood vessel;

Fig. 11 is a graph of pressure differential against time for a steady state vacuum;

25 Fig. 12 is a graph of pressure differential against time for a pulsatile pressure differential waveform generated by the invention;

Fig. 13 is a pressure differential waveform with negative and positive pressure differentials;

30 Fig. 14 is a pressure differential waveform with varying frequency;

Fig. 15 is a pressure differential waveform with different decay and rise times;

Fig. 16 is a pressure differential waveform with varying amplitude;

Fig. 17 is a pressure differential waveform with a truncated wave;

Fig. 18 shows a pressure differential waveform with a dwell time within the wave;

5

Fig. 19 is a diagram of a clot removal system of the invention;

Figs. 20A and 20B illustrate a piston type pulsatile vacuum generator;

10

Fig. 20C illustrates a cam type pulsatile vacuum generator;

Fig. 21 is a view of another pulsatile vacuum generator;

Figs. 22A and 22B illustrate another cam type pulsatile vacuum generator;

15

Fig. 23A illustrates a pulsatile aspiration system;

Figs. 23B and 23C illustrate an element of the pulsatile aspiration system of Fig. 23A;

20

Figs. 24A and 24B show pulsatile pressure waveforms;

Fig. 25 is a schematic of another pulsatile aspiration system of this invention;

Fig. 26 is a schematic of a portion of another pulsatile aspiration system of this invention;

25

Figs. 27A and 27B are views of a one way valve;

Fig. 28A illustrates a portion of a pulsatile aspiration system of this invention; and

30

Figs. 28B – 28D illustrate various states of an element of the pulsatile aspiration system of Fig. 28A.

Detailed description of the drawings

Specific embodiments of the present invention are now described in detail with reference to the Figures, wherein identical reference numbers indicate identical or functionality similar elements. The terms “distal” or “proximal” are used in the following description with respect to a position or direction relative to the treating physician. “Distal” or “distally” are a position distant from or
5 in a direction away from the physician. “Proximal” or “proximally” or “proximate” are a position near or in a direction toward the physician.

Accessing cerebral, coronary and pulmonary vessels involves the use of a number of commercially available products and conventional procedural steps. Access products such as
10 guidewires, guide catheters, angiographic catheters and microcatheters are described elsewhere and are regularly used in cath lab procedures. It is assumed in the descriptions below that these products and methods are employed in conjunction with the device and methods of this invention and do not need to be described in detail.

15 The following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Although the description of the invention is in many cases in the context of treatment of intracranial arteries, the invention may also be used in other body passageways as previously described.

20 Fig. 1; Item number 1 illustrates an example only of a lumen network similar in complexity to cerebral vasculature. Item number 2 is an illustration representing a clot that is lodged in the cerebral vasculature network. Item number 3 shows where the blood enters the network and item number 4 shows where the blood exits the network.

25 Fig. 2 illustrates a schematic representation of the steady state vacuum pump combined into a circuit with the pulse generation system. This circuit is then connected to the proximal end of a catheter. Item 11 is the vacuum pump for creating aspiration suction represented by the approved standard drafting symbol. Item number 12 is the cyclical reciprocation machine shown with a plunger 16 that moves to and fro in a piston chamber. Item number 13 is a fluid collection
30 container within the aspiration circuit which collects all the content aspirated from the body. Item number 14 is tubing in the aspiration circuit which is joined to the catheter proximal end at the same point where the reciprocation connects to the catheter proximal end. This is achieved using a Y junction connector shown here. Item 15 is a connection to the catheter proximal end.

The catheter then passes through a haemostasis valve to enter the bodies vascular system usually at the common iliac artery and not shown here.

Fig. 3 is a full schematic of the entire system including the vascular and cerebral circulation systems. The apparatus of the invention is shown in schematic form 50 and contains a steady state vacuum pump 32 and a pulsatile flow generator 31. The output of these pumps is combined and connected to the proximal end of a catheter 34 at the connector 51. The catheter is introduced into the vasculature at the haemostasis valve 40 and forwarded to the target location of the clot 41. When the catheter tip 35 approaches the clot 41, steady state vacuum from the pump 32 can be applied at the catheter tip. If the aspirate flow is blocked by the clot the pulsatile flow generator 31 can be engaged to produce a pressure differential waveform at the catheter tip to aspirate the clot 41.

Figs. 4 A to C is an illustration of a pulsatile flow generator that produces a pressure output which matches a sine wave configuration. Piston 65 is driven backwards and forwards by the rotating wheel 61 which contains a drive pin 63. This drive pin 63 engages in the slot of component 62, which is constrained so that it can only move in a linear direction. Therefore the rotational movement of wheel 61 is converted into linear motion of piston 65 which travels in the direction 66 as shown, as the wheel rotates. The fluid pressure output at 68 matches a sine wave.

20

Fig. 5 illustrates a number of possible wave form profiles representing positive and negative pressure pulses that are possible to generate with the reciprocation drive which have varying frequency.

Fig. 6 is one example of a motorised reciprocal drive 83 with variable speed. In this configuration the reciprocal drive shaft (not shown) is connected to the plunger of syringe 85. The drive is actuated using trigger 84 and moves the piston 81 backwards and forwards creating a pulsatile pressure output at the tip of syringe 85.

Fig. 7 shows the distal tip of a catheter touching or abutting a blood clot that is lodged in a circuit representing cerebral vascular complexity. Fig. 8 shows the distal tip of the catheter firmly engaged in a blood clot that is still lodged in the circuit. In this example 500mm Hg vacuum was applied to the catheter to aspirate the clot, however the application of this steady state aspiration energy was not sufficient to aspirate the clot. Fig. 9 shows that the clot in Fig. 8 has been fully

aspirated into the catheter after a small number of reciprocation pulses (3 to 5) had been applied at the tip of the catheter.

Fig. 10A shows a schematic illustration of an occlusive clot 201 lodged in a blood vessel 205. Catheter 203 has been introduced to the vasculature and the tip 202 is approaching the clot. Fig. 10B illustrates the catheter 210 in contact with the clot 214. A portion of the clot 212 has been aspirated into the catheter tip 211 blocking the tip and sealing the end of the catheter 210. As the catheter is blocked the pressure in the catheter P_A is different to the pressure in the blood vessel P_B . The pressure differential acting across the clot is a function of $(P_B - P_A)$ and this urges the clot to deform and flow or extrude into the catheter. Applying a pulsatile pressure differential increases the energy applied to the clot and helps the clot to deform and flow. Fig. 10C illustrates that when a pulsatile pressure differential is applied to the clot 220 it can deform at the interface 223 where the clot enters the mouth of the catheter 221 to facilitate full aspiration. The friction between the clot 224 and the inner surface of the catheter 222 is also reduced by the application of the pulsatile pressure differential facilitating full aspiration of the clot. Fig. 10D shows the clot 232 approaching full aspiration into the catheter.

Figs. 11 to 18 show a series of graphs of the pressure differential against time for a range of waveforms. The pressure differential ΔP is the pressure acting across the clot as shown in Fig. 10B and is related to the difference between the blood pressure in the vessel and the pressure in the catheter tip when the tip is occluded by the clot.

Fig. 11 shows a graph of pressure differential against time for a steady state vacuum. In this graph, the pressure differential increases 300 after the vacuum pump is switched on until it reaches a plateau 301 when steady state conditions are achieved.

Fig. 12 shows a graph of pressure differential against time for a pulsatile pressure differential waveform generated by the invention. The graph 320 is similar to a sine wave with a fixed frequency (F) and amplitude (A).

Fig. 13 shows a pressure differential waveform 340 illustrating that during part of the wave cycle a positive pressure differential 341 is applied across the clot at the catheter tip.

Fig. 14 shows a pressure differential waveform with varying frequency where frequency F_1 is different to F_2 and is changing with time.

Fig. 15 shows a pressure differential waveform with different decay and rise times. In the example shown the decay time t_1 is shorter than the rise time t_2 producing a saw tooth waveform.

Fig. 16 shows a pressure differential waveform with varying amplitude. The absolute values of the amplitude can change with time as shown here where A_1 , A_2 , and A_3 are all different. The maximum and minimum values of the amplitude can also change with time.

10

Fig. 17 illustrates a pressure differential waveform with a truncated wave. This waveform allows for dwell times 400 and 401 at the point of minimum and maximum pressure differential.

Fig. 18 shows a pressure differential waveform where a dwell time has been introduced within the wave. Multiple dwell times can be introduced in the cycle such as 450 and 451, or a single dwell time as shown 452.

Fig. 19 is an illustration of another configuration of the invention 500. In this schematic the pulse generator (labelled) is a separate apparatus to the vacuum pump. This pulse generator can produce a pressure differential waveform at the catheter tip as described elsewhere in this patent but is non blood contacting. The pulse generator creates the waveform by selective compression of the connector tubing. This creates the benefit of not having to sterilise part of the apparatus prior to use, as the connector tubing is disposable and single use only. The method of use is identical to that described before with the vacuum pump and pulse generator connected to the proximal end of a catheter which is introduced through the vasculature to the target location of the clot.

Fig. 20A shows internal details of the pulse generator illustrated in Fig. 19. In this configuration a reciprocating plunger 551 can compress the tubing 552 creating a pressure wave. The tubing 552 is elastic and recovers its shape as soon as the plunger moves up. The stroke of the plunger 560 shown in Fig. 20B can vary and different plunger widths or multiple plungers can provide displacement variations. Fig. 20C shows a variation of this design where the plunger is replaced with a cam 562. Rotation of the cam provides a pulse generation capability.

Fig. 21 shows the preferred design of this pulse generator which contains multiple cams in series. The cam 602 nearest the vacuum pump can rotate and seal the tubing 600 so that rotation of cams 604 and 605 can produce a positive pressure in the tubing. The tubing 600 is flexible and may be straight or have a stepped diameter as shown. The cams can be programmed so that
5 some or all can work at any given time, each with a different frequency, or not be operated at all.

To reduce friction between the cam and the flexible tubing, each cam could have a sliding outer layer as shown in Figs. 22A and B. The cam 651 rotates on the eccentric axle 650 compressing the tubing 653. To reduce the friction the cam has a low friction sliding outer ring 652 which
10 does not rotate relative to the tubing. Fig. 22B illustrates how the cam 670 position is rotated relative to Fig. 22A but the outer ring 672 has not rotated relative to the tubing wall 673.

Fig. 23a illustrates an apparatus 700 of this invention, comprising a vacuum pump 714 and a pulse generating system. Fig. 23b shows a more detailed view of the pulse generating
15 components of the system. The vacuum pump 714 may comprise a diaphragm or vane or piston pump, or a peristaltic pump, or other means of generating a negative pressure differential. This vacuum pump is connected by tube 705 to a reception canister 707, which is configured to receive aspirated blood or material. A safety valve may be provided within the canister to prevent fluid or material entering tube 705 and damaging the pump. Tube 706 connects the
20 canister to rotating valve 711. Tube 708 connects rotating valve 711 to a catheter (not shown) that is inserted within the patient, and does so either directly or via a further connecting tube or connector or rotating haemostasis valve or similar. Tube 708 is held in place by clips 709, which are configured so that the assembly of tube 708, rotating valve 711 and tube 707 can be easily assembled to or detached from the system (so that they may be disposable elements of the
25 system). When clipped into place tube 708 sits between a rotatable cam 710 and a support plate 712. In use the system is capable of supplying a steady state vacuum by means of the vacuum pump 714 once switch 701 is moved to the "ON" position. The vacuum pump evacuates the canister 707 via tube 705, and thus a suction or aspiration force is transmitted through tubes 706 and 708 (once rotating valve 711 and cam 710 are in the open position).

30

Fig. 23b and Fig. 23c illustrate the operation of the pulse generating system. Rotating valve 711 comprises a housing 715 with inlet and outlet tube connectors 717 and 716, and an internal rotating element 713. When rotating element 713 covers the mouth of either connector 717 or 716 the valve is closed and tube 708 is no longer exposed to the vacuum within canister 707.

Thus by rotating or oscillating element 713 a vacuum pulse may be delivered through tube 708, and this may be beneficial for the retrieval of stubborn clot material as previously described. However the nature and condition of the material being aspirated may affect the waveform of the pulse generated in tube 708 and transmitted to the treatment catheter and thus to the patient. Fig. 24b illustrates a representative pulse generated by a vacuum pump with a simple on/off valve such as rotating valve 711. The vertical axis 851 denotes pressure and the horizontal axis 850 denotes time. Prior to initiating any pulse a relatively steady state vacuum level 853 is provided in tube 708. Closure of valve 711 disconnects the tube from the vacuum source. In a case (case 1) where the tube 708 is connected to a catheter which is aspirating liquid blood or very soft clot the closure of valve 711 will cause the vacuum in the catheter to decay quickly, and angle 857 will be steep, allowing the vacuum to decay quickly from level 854 to 855. Once valve 711 is opened the vacuum is restored and the vacuum level in the catheter quickly returns to original level 853. In a case (case 2) where the tube 708 is connected to a catheter which is aspirating a resistant material such as fibrin rich thrombus the closure of valve 711 will cause the vacuum in the catheter to decay more slowly than in the previous case, and angle 857 will be more shallow, so that the rate of decay of the vacuum is significantly reduced. A rate of change of vacuum level of greater than 100mmHg / second is necessary in order to create an effective pulse in the catheter. A rate of change of greater than 200mmHg / second is preferred, and a rate of change of greater than 400mmHg / second is more preferred, while a rate of change of greater than 600mmHg / second is most preferred.

The rotatable cam 710 and support plate 712 provide a means of increasing the rate of decay of the vacuum in tube 708 and any catheter to which it is connected, particularly in the scenario in which tube 708 is connected to a catheter which is aspirating a resistant material such as fibrin rich thrombus. This is achieved by creating a positive pulse of pressure to counteract the vacuum. This is achieved by rotation of the cam 710 to compress tube 708 between the cam and support plate 712, which in turn compresses the liquid or gas within tube 708 and thus rapidly reduces the vacuum level within the tube. Fig. 23c illustrates this compression in action. The cam may be timed to compress the tube 708 at the same time as valve 711 closes, or fractionally later than closure of valve 711. The cam 710 may be timed to release the compression of tube 708 before, simultaneously or after the opening of valve 711. The impact of this system on the pulsatile waveform generated is illustrated in Fig. 24a.

The vertical axis 751 denotes pressure and the horizontal axis 750 denotes time. Prior to initiating any pulse a relatively steady state vacuum level 753 is provided in tube 708. Closure of valve 711 disconnects the tube from the vacuum source. In a case (case 3) where the tube 708 is connected to a catheter which is aspirating a resistant material such as fibrin rich thrombus the closure of valve 711 will cause the vacuum in the catheter to start to decay slowly at a first rate of decay illustrated by the line between points 754 and 755. Rotation of cam 710 to compress tube 708 causes the rate of decay of the vacuum to be significantly increased, illustrated by the line between points 755 and 756. A dwell period may be provided between points 756 and 757, after which cam 710 is rotated to remove the compression from tube 708 and valve 711 is opened, allowing the vacuum level in tube 708 to drop quickly from point 757 to point 758. Again a dwell period may be provided at vacuum level 753 before additional pulses are provided.

Fig. 25 is a schematic drawing of another pulsatile aspiration pump system 900 of this invention configured to provide pulses with a rapid rate of change of vacuum level. Catheter 901 is shown in the process of aspirating thrombus 907. This aspiration is caused by a pressure differential between the medium in which the thrombus is located outside the catheter and that of the internal lumen of the catheter. An aspiration force is provided to the catheter through tube 903, which is in turn connected to tube 908, which is itself connected to canister 904. Canister 904 is evacuated by pump 905. A second "pump" 902 is located between tubes 903 and 908 and consists in this embodiment of a piston pump, similar to a syringe. A pair of one way valves 906 and 909 are positioned either side of piston pump 902, so that when the piston moves downwards a small but limited positive pressure is applied to tube 903 and hence to catheter 901 before the valve 906 closes. This causes a rapid rate of change in the vacuum level within the catheter 901. Conversely when the piston moves upward the system will aspirate preferentially from the catheter rather than the canister, creating a rapid increase in the vacuum level within the catheter.

Fig. 26 is a schematic drawing of another pulsatile aspiration pump system 950 of this invention very similar to system 900. An aspiration force is provided through tube 953, which is in turn connected to tube 958, which is itself connected to canister 954. Canister 954 is evacuated by pump 955. A second "pump" 952 is located between tubes 953 and 958. Pump 952 consists in this embodiment of an oscillating diaphragm assembly 963, which is supported by compression spring 960 and actuated by the counteracting forces of this spring 960 and cam 961. Cam 961 may be operated by many means, including the gear assembly 962 illustrated herein. A pair of

one way valves 956 and 959 are positioned either side of pump 952, so that when the diaphragm moves downwards a small but limited positive pressure is applied to tube 953 before the valve 956 closes. This causes a rapid rate of change in the vacuum level within the catheter 951. Conversely when the diaphragm moves upward the system will aspirate preferentially from the catheter rather than the canister, creating a rapid increase in the vacuum level within the catheter.

Figs. 27a and 27b are schematics of a simple one way valve 1000 of this invention. They are configured to open easily to allow flow in one direction, and close quickly and automatically once the direction of the pressure gradient (and hence the direction of flow) across the valve changes. Valve 1000 comprises a body section 1001 with a pair of tube connectors 1002 and 1003 at either end. The body 1001 has a generally square or rectangular section, so that flap 1004 can be hinged at an outer edge and move freely from an open to a closed position. A stop 1005 is provided so that the flap is prevented from reaching a fully open position where a change in flow direction would not cause it to close. A second stop 1006 prevents the flap from moving beyond the fully closed position once the pressure gradient is reversed.

Fig. 28a is a schematic of a portion of a pulsatile pump system 1050 of this invention. Canister 1051 is connected to a vacuum pump (not shown) by connecting tube 1052, and to a treatment catheter (not shown) by connecting tube 1053. In use a vacuum is generated within the canister by the vacuum pump and thus blood and thrombus are aspirated through a treatment catheter and through tube 1053 into the canister. A pulsatile waveform as described in relation to Fig. 24b can be generated by oscillation back and forth of obturator 1055, which is guided through the canister by guide port 1056, and enters the mouth of tube 1053 on the other side of the canister. The obturator can be moved back and forth by a simple gear mechanism as shown or by any of the other means of reciprocation well known in the art. Figs. 28b-d show the obturator of Fig. 28a in various different positions, and also show a corrugated element 1056 which may be used to ensure that movement of the obturator does not create leakage into the canister.

Fig. 28b (and Fig. 28a) show the obturator in the open position where only the narrow guide portion 1057 is positioned within the mouth of tube 1053. In this position a steady state vacuum may be maintained with little or no restriction from the obturator. Fig. 28c shows the obturator in the closed position where the tapered portion 1058 of the obturator is fully within the mouth of tube 1053. In this position tube 1053 is no longer subject to the vacuum within the canister and the vacuum level within the tube (and connected catheter) will start to decay. The rate of decay

of this vacuum can be significantly accelerated by further advancement of the obturator to the position shown in Fig. 28d, which provides a positive displacement to the fluid (or gas) within tube 1053, having a similar effect to the piston and diaphragm movements described in systems 700, 900 and 950.

5

It will be apparent from the foregoing description that while particular embodiments of the present invention have been illustrated and described, various modifications can be made without departing from the spirit and scope of the invention. For example, while the embodiments described herein refer to particular features, the invention includes embodiments having different combinations of features. The invention also includes embodiments that do not include all of the specific features described.

10

The invention is not limited to the embodiments hereinbefore described which may be varied in construction and detail.

15

Claims

1. A system for removing occlusive clot from a blood vessel comprising:-
a catheter; and
5 an apparatus for generating a pulsatile vacuum force to pulse the pressure gradient at a distal end of the catheter.
2. A system as claimed in claim 1 wherein the apparatus comprise a vacuum pump and a pulse generator.
- 10 3. A system as claimed in claim 2 wherein the pulse generator is integral with the vacuum pump.
4. A system as claimed in claim 2 wherein the pulse generator is separate from the vacuum pump.
- 15 5. A system as claimed in claim 4 wherein the pulse generator is located between the vacuum pump and the proximal end of the catheter.
- 20 6. A system as claimed in claim 4 or 5 comprising a flexible tubing between the vacuum pump and the proximal end of the catheter.
7. A system as claimed in claim 6 wherein the pulse generator is applied to the flexible tubing.
- 25 8. A system as claimed in claim 7 wherein the pulse generator comprises a reciprocating plunger.
9. A system as claimed in claim 7 wherein the pulse generator comprises a rotatable cam.
- 30 10. A system as claimed in claim 9 wherein the cam comprises an outer bearing to minimise drag on the tubing.
11. A system as claimed in claim 10 wherein the outer bearing comprises a sliding outer layer.
- 35 12. A system as claimed in any of claims 7 to 11 wherein the flexible tubing is of uniform cross section along the length thereof.

13. A system as claimed in any of claims 7 to 11 wherein the flexible tubing is of variable cross section along the length thereof.
- 5 14. A system as claimed in any of claims 1 to 13 comprising a controller for controlling the apparatus for generating a pulsatile vacuum source.
15. A system as claimed in claim 14 wherein the controller is adapted to vary the pressure over time in a waveform.
- 10 16. A system as claimed in claim 15 wherein the waveform has a fixed frequency and amplitude, and equal rise and decay times.
17. A system as claimed in claim 15 wherein the waveform has a varying frequency with time.
- 15 18. A system as claimed in claim 15 wherein the waveform has varying amplitude with time.
19. A system as claimed in claim 15 wherein the waveform has different rise and decay times.
- 20 20. A system as claimed in claim 15 wherein the waveform rise and decay times change with time.
- 25 21. A system as claimed in claim 15 wherein the waveform is a truncated or square waveform incorporating a dwell time at the peak and trough of each wave.
22. A system as claimed in claim 15 wherein the waveform incorporates one or more dwell times within each wave producing a stepped wave configuration.
- 30 23. A method for removing occlusive clot from a blood vessel comprising the steps of:-
delivering a catheter to a location adjacent to an occlusive clot; and
applying a pulsatile vacuum to the clot using the catheter.
- 35 24. A method as claimed in claim 23 comprising the step of varying the pressure over time in a waveform.

25. A method as claimed in claim 24 wherein the waveform has a fixed frequency and amplitude, and equal rise and decay times.
26. A method as claimed in claim 24 wherein the waveform has a varying frequency with time.
27. A method as claimed in claim 24 wherein the waveform has varying amplitude with time.
28. A method as claimed in claim 24 wherein the waveform has a different rise and decay time.
29. A method as claimed in claim 24 wherein the waveform rise and decay times change with time.
30. A method as claimed in claim 24 wherein the waveform is a truncated or square waveform incorporating a dwell time at the peak and trough of each wave.
31. A method as claimed in claim 24 wherein the waveform incorporates one or more dwell times within each wave producing a stepped wave configuration.
32. A system for removing occlusive clot from a blood vessel comprising:-
a catheter for applying a vacuum to an occlusive clot; and
an apparatus for generating an additional energy to be applied to the clot.
33. A system as claimed in claim 32 wherein the apparatus is adapted to apply a variable pressure to the clot at the distal tip of the catheter.
34. A system as claimed in claim 32 or 33 wherein the variable pressure applied by the apparatus produces a variable pressure differential between the catheter and the blood pressure around the clot.
35. A system as claimed in claim 34 wherein the variable pressure differential provides additional energy to the clot to overcome the extrusion energy required to deform and aspirate the clot.

36. A system as claimed in claim 34 wherein applying a variable pressure differential to the clot changes the friction between the clot and the catheter from static to dynamic friction reducing the total friction and facilitating aspiration into the catheter.
- 5 37. A system as claimed in claim 34 wherein applying a variable pressure differential to the clot increases the porosity of the clot reducing the deformation force required to aspirate the clot.
38. A system as claimed in claim 34 wherein a plot of pressure differential against time
10 produces a waveform.
39. A system as claimed in claim 38 wherein the pressure differential waveform is similar to a sine wave with fixed frequency and amplitude, and equal rise and decay times.
- 15 40. A system as claimed in claim 38 wherein the pressure differential waveform has a varying frequency with time.
41. A system as claimed in claim 38 wherein the pressure differential waveform has varying amplitude with time.
20
42. A system as claimed in claim 38 wherein the pressure differential waveform has a different rise and decay time.
43. A system as claimed in claim 38 wherein the pressure differential waveform rise and
25 decay times change with time.
44. A system as claimed in claim 38 wherein the pressure differential waveform is a truncated or square waveform incorporating a dwell time at the peak and trough of each wave.
30
45. A system as claimed in claim 38 wherein the pressure differential waveform incorporates one or more dwell times within each wave producing a stepped wave configuration.

46. A system as claimed in claim 34 and 38 wherein the pressure in the catheter tip is always less than the surrounding blood pressure.
47. A system as claimed in claim 34 and 38 wherein the pressure in the catheter tip is greater
5 than the surrounding blood pressure for a fraction of the waveform.
48. A system as claimed in claim 38 wherein the pressure differential waveform is a combination of some or all the waveforms detailed in claims 39 to 45.
- 10 49. A system as claimed in claim 48 wherein the pressure differential waveform is pre-programmed in the apparatus
50. A system as claimed in claim 49 wherein the pre-programmed pressure differential waveform is optimized for a particular clot type.
- 15 51. A system as claimed in claim 38 wherein the pressure differential waveform is produced in the apparatus by moving one or more pistons in a fluid chamber similar to a syringe.
52. A system as claimed in claim 51 where the piston is driven by a rotating mechanical drive
20 system
53. A system as claimed in claim 51 where the piston is driven by a electromechanical means such as a linear drive system
- 25 54. A system as claimed in claim 51 where the piston is driven by piezoelectric means.
55. A system as claimed in claim 51 where the piston is driven by a pneumatic cylinder.
56. A system as claimed in any of claims 32 to 55 wherein the apparatus is separate from the
30 catheter.
57. A system as claimed in any of claims 32 to 56 wherein the apparatus is integral with the catheter.

58. A system as claimed in claim 57 wherein the catheter contains a piston.
59. A system as claimed in claim 58 wherein the piston is actuated by a drive system external to the catheter.
- 5 60. A system as claimed in claim 32 wherein the additional energy applied to the clot is a vibration force.
61. A system as claimed in claim 60 wherein the catheter incorporates a vibrating tip.
- 10 62. A system as claimed in claim 60 wherein the frequency of the vibrating tip can vary from 5 Hz to greater than 20,000 Hz.
- 15 63. A system as claimed in claim 61 wherein the vibrating tip contains one or more aspiration lumens with a total cross sectional area greater than 0.78mm².
64. A system as claimed in claim 34 wherein the apparatus comprises a steady state vacuum generator and a pulsatile flow generator.
- 20 65. A method for removing an occlusive clot from a blood vessel comprising the steps of :
delivering a catheter to a location adjacent to an occlusive clot;
applying a vacuum to the clot using the catheter; and
applying an additional energy to the clot.
- 25 66. A method as claimed in claim 65 wherein the additional energy is applied to the clot via the catheter.
67. A method as claimed in claim 66 wherein the additional energy is applied to the clot via the catheter as the catheter approaches the clot.
- 30 68. A method as claimed in claim 66 wherein the additional energy is applied to the clot via the catheter only after the catheter fails to aspirate the clot with steady state vacuum.

69. A method as claimed in claim 65 wherein the additional energy is applied to a guide catheter or sheath positioned proximal of the clot in the vasculature.
70. A method as claimed in claim 65 wherein the additional energy is applied to a guide catheter or sheath and intermediate catheter simultaneously.
71. A method as claimed in claim 65 wherein the additional energy is applied to the clot via the catheter in conjunction with the use of a stentriever device.
72. A method as claimed in claim 65 wherein the additional energy is applied to the clot through the catheter.
73. A method as claimed in any of claims 65 to 72 comprising:
- a. delivering the auxiliary apparatus to a location adjacent to the clot; and
 - b. applying the additional energy directly to the clot.
74. A method as claimed in claim 73 comprising delivering the catheter and the auxiliary apparatus simultaneously.
75. A system as claimed in any of claims 1 to 22 or 32 to 64 comprising a canister which is configured to receive aspirated blood or material.
76. A system as claimed in claim 75 wherein the system comprises a vacuum pump which is connected to the canister.
77. A system as claimed in claim 76 wherein the vacuum is drawn through the canister.
78. A system as claimed in any of claims 1 to 22, 32 to 64, or 75 to 77 comprising a first vacuum pulse generator.
79. A system as claimed in claim 78 comprising a second vacuum pulse generator.
80. A system as claimed in claim 79 wherein the vacuum pulse generators are configured to operate separately, at the same time, or at different times to vary the vacuum pulse generated.

81. A system as claimed in any of claims 78 to 80 wherein the first pulse generator comprises a valve having a housing and an element which is rotatable and/or oscillatable in the housing.
- 5 82. A system as claimed in any of claims 78 to 81 wherein the second pulse generator is adapted to engage a flexible tube.
83. A system as claimed in claim 82 wherein the second vacuum pulse generator comprises a rotatable cam.
- 10 84. A system as claimed in claim 78 wherein the first vacuum pulse generator comprises a pump.
85. A system as claimed in claim 84 further comprising non-return valves located on both
15 sides of the pump.
86. A system as claimed in claim 78 comprising a canister configured to receive aspirated blood or material and the first pulse generator comprises an obturator which is movable
20 through the canister.
- 25

Abstract

A system for removing occlusive clot from a blood vessel comprises a catheter and an apparatus for generating a pulsatile vacuum force to pulse the pressure gradient at a distal end of the catheter. The pulse generator may be integral with or separate from the vacuum pump. The
5 pulse generator may be applied to a flexible tubing between the vacuum pump and the proximal end of the catheter.




Fig. 1




Fig. 2




Fig. 3




Fig. 4A




Fig. 4B





Fig. 4C






Fig. 6




Fig. 7




Fig. 8




Fig. 9

Fig. 10A




Fig. 10B




Fig. 10C





Fig. 10D






Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17






Fig. 18






Fig. 21




Fig. 22A

Fig. 22B




Fig. 23A







Fig. 23B






Fig. 25




Fig. 26




Fig. 27A




Fig. 27B




Fig. 28A




Fig. 28B




Fig. 28C




Fig. 28D

Electronic Acknowledgement Receipt	
EFS ID:	28696168
Application Number:	62474383
International Application Number:	
Confirmation Number:	5049
Title of Invention:	CLOT RETRIEVAL SYSTEM FOR REMOVING CLOT FROM A BLOOD VESSEL
First Named Inventor/Applicant Name:	Eamon Brady
Customer Number:	108449
Filer:	Jessica Winchester/Monique Blakey
Filer Authorized By:	Jessica Winchester
Attorney Docket Number:	00007-0037-00600
Receipt Date:	21-MAR-2017
Filing Date:	
Time Stamp:	17:00:45
Application Type:	Provisional

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	\$ 130
RAM confirmation Number	032217INTEFSW17013700
Deposit Account	
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Application Data Sheet	ADS.pdf	116753	no	10
			aea2c280901b0739c13da2dedc64b15c1258a2fe		
Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
2	Provisional Cover Sheet (SB16)	CS.pdf	90249	no	4
			bb0055edd1ed8688720c34bad35e7ea4125acca4		
Warnings:					
This is not a USPTO supplied Provisional Cover Sheet SB16 form.					
Information:					
3	Specification	spec.pdf	223416	no	34
			fe91a6956490ea675028a9921bdd1cd016ea87a9		
Warnings:					
Information:					
4	Drawings-only black and white line drawings	drawings.pdf	1375492	no	18
			76e33616f3c3143e6397c425fa99bbd1c24e1bed		
Warnings:					
Information:					
5	Fee Worksheet (SB06)	fee-info.pdf	29891	no	2
			951564ec2c45a7b6691041f46a0eb9bbc1a149b8		
Warnings:					
Information:					
Total Files Size (in bytes):			1835801		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.